March 10, 2022– The 14 drug companies that have imposed or announced restrictions on safety-net hospital access to 340B drug pricing program discounts collectively brought in more than a half-trillion dollars in revenues in 2021. The banner year for the drugmakers occurred as hospitals reported increasing losses of 340B savings from the cuts. Last month, most drug companies … [Read more...]
Seventh Drug Company Told It is Violating 340B Law
Oct. 12, 2021– Eight drug companies have restricted access to discounts to safety-net providers through the 340B drug pricing program on drugs dispensed at community-based pharmacies. Now the government officially has informed all but one of those companies that they are in violation of federal law and must restore the discounted pricing. The most recent recipient of a … [Read more...]
Merck Plan to Withhold 340B Discounts Adds to Threat to Diabetes Patients
August 26, 2021 - The global pharmaceutical manufacturer Merck is the latest company to announce it will stop offering 340B discounts to hospitals on drugs dispensed to patients at community pharmacies. The move comes three months after the federal government warned drug companies that such actions are unlawful under the 340B drug pricing program statute. Merck will become the … [Read more...]
Outcry Intensifies Over Pharma Moves Against 340B
September 10, 2020— Five major pharmaceutical companies are flouting the 340B drug pricing program statute, and others appear poised to follow suit. But a vocal group of safety-net providers and national organizations are calling on the federal government to use its authority to put a stop to those actions before patients are harmed. Beginning in late June, the drug makers … [Read more...]